New Delhi, Sept. 26 -- Indian Pharmaceutical Alliance has said that the US President Donald Trump's announcement of tariffs of up to 100 per cent on imports of branded and patented pharmaceuticals starting October 1 specifically refers to patented or branded products, and not impact generic medicines.

Indian Pharmaceutical Alliance (IPA) Secretary General Sudarshan Jain said, "The executive order refers to patented / branded products supplied to the US. It is not applicable to generic medicines."

India supplies over 45 per cent of generic and 15 per cent of biosimilar drugs, which are used in the United States.

Chairperson of the topmost Pharmaceutical company, Pharmexcil, which earns 40 - 50 per cent of its total revenues from the Ame...